跳至主要内容
临床试验/NCT02018172
NCT02018172终止不适用

Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device

Ferring Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
3
试验地点
1
主要终点
Rate of overall treatment adherence

研究概览

简要总结

The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or Turner's syndrome.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient with growth hormone deficiency,
  • Diagnosis of growth hormone deficiency proven by appropriate exploration
  • Size ≤ -2 Standard Deviation (SD) according to the French references
  • Growth velocity in the previous year inferior to the normal for age (-1SD) or < 4cm/year
  • Growth deficiency due to Turner's syndrome
  • Turner's syndrome confirmed by a karyotype
  • Patient's size ≤ -2 SD according to the French references
  • Bone age < 12 years
  • Patient who require a minimum of 18 months of treatment.

排除标准

  • There are no exclusion criteria except the contraindication for Zomacton® 10 mg

研究组 & 干预措施

Zomacton® treatment with Zomajet® Vision X device

干预措施: somatropin (Drug)

结局指标

主要结局

Rate of overall treatment adherence

时间窗: Up to 18 months

Ratio between actual duration of administration and total duration recommended by physician

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验